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Abstract
Background: Chronic obstructive pulmonary disorder (COPD) affects over 1 million people in the United Kingdom, and 1
person dies from COPD every 20 minutes. The cost to people with COPD and the National Health Service is huge – more than
24 million working days lost a year and the annual expenditure on COPD is £810 million and £930 million a year.
Objective: We aim to identify patients with COPD who are at risk of exacerbations and hospital admissions as well as those
who have not been formally diagnosed, yet remain at risk.
Methods: This mixed-methods study will use both data and interviews from patients and health care professionals. The project
Modern Innovative SolutionS in Improving Outcomes iN COPD (MISSION COPD) will hold multidisciplinary carousel style
clinics to rapidly assess the patients’ COPD and related comorbidities, and enhance patient knowledge and skills for
self-management.
Results: This study is ongoing.
Conclusions: This research will capture quantitative and qualitative outcomes to accompany a program of quality improvement
through delivery of novel care models.
(JMIR Res Protoc 2017;6(6):e104)   doi:10.2196/resprot.6850
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Introduction
Epidemiology of COPD and Prevalence Gap
In the United Kingdom, 1 million people have diagnosed chronic
obstructive pulmonary disease (COPD), which accounts for
25,000 deaths annually [1], making it the 5th commonest cause
of death and 2nd largest cause for hospital admissions. Annual
health care expenditure on COPD is £810 million [2] (equivalent
to £1.3 million per 100,000 population). Severe, exacerbation
prone COPD costs ten times more to treat than mild disease.
COPD causes 24 million lost working days annually, more than
any other respiratory condition, costing the economy £3.8 billion
[2]. Worse still, cases of COPD will increase by more than 30%
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in the next 10 years [3], while an estimated 2 million individuals
presently remain undiagnosed. Hospital admissions due to
COPD have increased by 13% since 2008 [3].
Portsmouth has significantly higher than United Kingdom
national averages for prevalence of smoking (main risk factor
for COPD), COPD admissions, readmissions, and deaths from
COPD (eg, 74.2 vs 51.5/100,000 population) [4]. COPD also
contributes to the gap in life expectancy in those living in areas
of highest and lowest deprivation confirming significant
inequalities [5]. There are still many general practices with a
“prevalence gap” between expected and actually diagnosed
COPD patients.
The cost burden of COPD to the Portsmouth Hospitals Trust
and to the community is high. In 2013/2014, there were 946
hospital contacts for COPD at a cost of £2,176,675. This
includes 286 admissions for COPD with respiratory failure—this
is associated with a longer length of stay and higher costs of
ventilatory support in a high-care environment. In Portsmouth
City, there are approximately 4000 patients with a known
diagnosis of COPD.
The identification of patients with undiagnosed COPD will lead
to an increase in costs in the short term including medication,
smoking cessation, referrals to pulmonary rehabilitation, and
flu vaccination. However, in the longer term, it will lead to
health care savings by preventing acute admissions as the first
diagnosis of COPD (15% of COPD diagnosis are made during
an acute admission [1]) and slowing disease progression. A
case-finding exercise in nearby Southampton increased COPD
prevalence in the area by 50% but reduced acute admissions
significantly [6].
The goal of Modern Innovative SolutionS Improving Outcomes
iN COPD (MISSION COPD) is to target patients who are high
risk and severe patients who have a higher chance of admission
and especially of admission with respiratory failure.
Mission Copd
MISSION COPD is a quality improvement project funded by
the Health Foundation to trial an innovative way of finding and
assessing patients with COPD and also case finding new
diagnoses of COPD. MISSION COPD will allow swift early
specialist multidisciplinary interventions in primary care to
diagnose and treat those at greatest risk, consistent with the
United Kingdom’s National Health Services (NHS) “5-year
Forward View”, calling for removal of traditional primary and
secondary care barriers. MISSION COPD will target COPD
patients with risk factors for exacerbations and deteriorating
lung function as well potential new diagnoses of COPD.
A Cochrane review published in October 2013 identified 25
randomized controlled trials of integrated disease management
interventions in COPD [7]. The Cochrane review concluded
that integrated disease management improved quality of life
and reduced hospital admissions and highlighted the following
areas as important: education/self-management, exacerbation
action plan, exercise, psychosocial/ occupational, smoking,
optimal medication, nutrition, follow-up, case management,
and multidisciplinary approaches.
The MISSION clinics provide all of the important factors
identified by the Cochrane review.
Stage 1: Identifying Those at Risk
The GRASP-COPD tool, recommended by NHS-IQ
(NHS-Improving Quality) will be used to identify patients in a
standardized format from practice computer systems using
pre-identified Read Codes. Read codes are codes used by all
general practitioner (GP) medical record systems to code contact
with patients. These are standard across all GP software
platforms (eg, EMIS, EMIS Web, SystemOne, Vision).
High-risk COPD patients will then be identified by criteria
including smoking status, prescribed medications, frequent
antibiotics, prescription of oral steroids, hospital or emergency
department (ED) admissions, lung function, and symptoms.
Potential new diagnoses of COPD will be identified by searching
for patients over 35 with a smoking history and contact with
the practice for respiratory symptoms such as bronchitis. Many
patients will have ≥2 risk factors. A specialist nurse will review
the results to check that patients meet the criteria and to exclude
any patients who are under hospital follow-up. All hospital
letters are stored on the GP medical records. An invitation to
attend the MISSION COPD clinics will then be sent by GP
practices.
Stage 2: Rapid Access COPD Clinics–Rapid Primary
Care Clinics
MISSION Rapid Access COPD Clinics will provide a
comprehensive, multidisciplinary assessment of patients with
high-risk COPD and not known to secondary care teams,
delivered in a carousel fashion at five GP practices on weekends
to overcome barriers in accessing health care such as transport
and carer availability (see Figure 1).
At each station, the patients will undergo:
• medical review with comorbidity assessment (eg,
gastroesophageal reflux, sleep apnea, anxiety, and
depression)
• questionnaire assessments of disease control (COPD
Assessment Test [CAT]), quality of life (St George’s
Respiratory Questionnaire [SGRQ]), physical activity
(Veterans Specific Activity Questionnaire [VSAQ]), and
comorbidity, eg, Hospital Anxiety and Depression Score
(HADS), gastroesophageal reflux disease questionnaire
(GERD-Q), Epworth Sleepiness Score (ESS) for sleep
apnea, and Patient Activation Measurement (PAM) for
self-management
• spirometry (FEV1, FVC, FEV1/FVC ratio) and exhaled
nitric oxide measurement
• inhaler technique assessment and teaching
• smoking cessation advice and referral where needed
• group education: disease process, exacerbations, treatment
options, self-management, pulmonary rehabilitation, and
breathing control
• receipt of a personalized MISSION COPD Health Plan
(copied to GP) encompassing all relevant information and
direct referral for pulmonary rehabilitation if necessary
• invitation to participate in clinical research by research
team, if eligible to take part in any studies
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Figure 1. RACC Structure.
Stage 3: Severe COPD Assessment
Clinics‒Comprehensive Secondary Care Clinics
Those with severe disease (according to national guidelines) or
multiple comorbidities will be invited for further comprehensive
review at MISSION Severe COPD Assessment Clinics, again
delivered in carousel-style stations, that may include additional
full lung function testing, clinical psychology, dietitian, exercise
education, medicines use review, social care advice, and same
day computerized tomography (CT) scan of the chest, blood
test, and echocardiogram. Both clinics will end with an
individualized multidisciplinary team assessment of each patient
to plan their future care pathway.
Follow-Up
After the MISSION COPD clinics, all patients receive a
personalized care plan and the results of the investigations. A
copy is also sent to the GP. As part of the service evaluation, a
questionnaire will be sent to the patients at 3 and 6 months to
measure any change in symptoms or disease control (CAT and
SGRQ) as well as self-reported exacerbation history and
satisfaction with the clinics. The GP records will be reviewed
at 6 months to assess any improvement in exacerbations,
hospitals admissions, or GP contact following the clinics.
MISSION COPD Research Study Overview
MISSION is a new and novel way of delivering highly
specialized COPD care and has the potential to change the way
COPD care across the United Kingdom is delivered as well as
services for other long-term health conditions. The MISSION
model is the first model of this type, and the current research
study aims to evaluate its success.
The study is a mixed-methods evaluation of the new service
comparing outcomes before and after the MISSION clinic using
data analysis and self-completion questionnaires.
Retrospective quantitative analysis of the data collected during
the MISSION clinics will be analyzed looking for COPD
phenotypes and contributing comorbidities. The data collected
at the initial visit and 3 and 6-month follow-up will be analyzed
looking for improvement in COPD control and quality of life
following patient attendance at MISSION clinics.
A self-completion questionnaire will be filled in after the clinic
by participants in the research study to assess their views on the
clinic and where they would like changes to be made. A
questionnaire will also be given to health care professionals to
seek their views on the clinic.
Qualitative interviews will be conducted with a sample of
willing participants to explore the experiences and acceptability
of the participants and health care professionals. The interviews
with health care professionals will explore their thoughts on
MISSION and its strengths and weaknesses as well as any
suggestions for improvement.
Study Aims and Objectives
Aims
Our aim is to use quantitative methods to explore the impact of
the MISSION service on clinical outcomes and to retrospectively
analyze the data collected (as part of their clinical care) from
all patients attending MISSION on COPD control, medication
usage and technique, exacerbations, comorbidities, allergies,
and investigations (blood tests, radiological imaging, lung
function). Additionally, we wish to conduct a prospective
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qualitative study exploring patients’ and health care
professionals’ views on MISSION.
Primary Objectives
Our two primary objectives of this study are to assess (1)
whether the number of COPD exacerbations (prednisolone or
equivalent ≥30 mg for >3 days or antibiotics for >3 days)
improves in MISSION patients in the 6 months after the clinic
compared with the 6 months before and (2) whether hospital
admissions change in the 6 months after the clinic.
Secondary Objectives for Patients With Known COPD
For those patients previously diagnosed with COPD, our
objectives are to assess the following:
1. whether the number of nonelective GP visits for COPD
change in the 6 months after the clinic
2. severity of COPD by Global initiative for Obstructive Lung
Disease and British Thoracic Society stage in the MISSION
clinics
3. medication and therapy used for COPD in the MISSION
clinics and changes made by clinics
4. number of antibiotic courses without prednisolone for lower
respiratory tract infections in 6 months before and after
MISSION [8]
5. Patient Activation Measure before and after MISSION [8]
6. frequency and severity of comorbidities in the COPD
population measured with validated questionnaires (GERD,
HADS, ESS) and suspected or confirmed through clinical
review
7. COPD control by CAT questionnaire at 3 and 6 months
8. exercise tolerance at 3 and 6 months
9. change in comorbidities at 3 and 6 months
10. inhaler technique – correct technique or correct device
11. lung function and phenotypes of COPD patients seen in
MISSION clinic
12. frequency of smoking and referrals for smoking cessation
13. acceptability of MISSION as a service model for patients
and staff
14. patient experiences of the MISSION service
15. health economic impact of the MISSION service
Secondary Objectives for Patients With Newly Diagnosed
COPD
Additionally, we aim to assess (1) the number of patients with
newly diagnosed COPD, (2) how long symptoms were present
before diagnosis, (3) frequency of smoking and referrals for
smoking cessation, (4) antibiotic history, medication history,
and number of contacts with respiratory symptoms prior to
diagnosis, and (5) lung function and phenotypes.
Methods
Design
This is a mixed-methods study. It comprises a quantitative
analysis of medical records relating to COPD in patients
attending the MISSION clinics for baseline health care usage,
and further episodes at 3 and 6 months. Self-completion
questionnaires will be used to explore participant and health
care professionals’ views on MISSION using closed and open
questions. Qualitative telephone interviews and focus group
interviews will be used to explore the experiences and
acceptability of patients and health care professionals.
Setting
Data for quantitative analysis will be collected from clinical
records made by the clinical team during the MISSION clinics
and follow-up questionnaire assessments. GP records will be
entered as usual by GP practices. The self-completion
questionnaire will be completed by participants in the MISSION
research study at the end of the MISSION clinic visit.
Participants will also be invited to give their views on MISSION
in a one-to-one interview. The interviews will be held after the
clinic by telephone within 2 months of the clinic. Health care
professionals will be invited to take part in group interviews at
the end of the clinic.
Participants
Participants will be patients who attend MISSION COPD clinics,
identified as having uncontrolled or potentially severe COPD
or unrecognized COPD from GP records by the MISSION
clinical team or health care professionals who attend the clinic
in a clinical capacity. Each patient will act as their own control,
with their disease control pre- and post-MISSION clinic
providing the comparator data [8].
Inclusion Criteria: Patients
The participant must meet all of the following criteria to be
considered eligible for the study: male or female, aged 18 years
or above; attended the MISSION clinic as a patient; and
participant is willing and able to give informed consent for
participation in the study. The participant may not enter the
study if unable or unwilling to give consent.
Inclusion Criteria: Health Care Professionals
The participant must meet all of the following criteria to be
considered eligible for the study: male or female, aged 18 years
or above; attended the MISSION clinic as a health care
professional; and participant is willing and able to give informed
consent for participation in the study. The participant may not
enter the study if unable or unwilling to give consent.
Sample Size
All 150 patients who are booked to attend the MISSION COPD
clinic will be invited to take part in the study. All health care
professionals from primary and secondary care who attend the
clinics in a professional capacity will be approached for
participation in the self-completion questionnaire and group
interview.
The sample size was based on comparing the number of
exacerbations in the 6-month period before and after the
MISSION intervention. Based on clinical experience, we expect
the number of exacerbations in the “pre” period to be
approximately 1.0. It is conservatively assumed that the standard
deviation of the differences in number of pre- and
post-exacerbations will have an equivalent value (ie, SD 1.0).
A clinically important improvement would be obtained post
intervention if the number of exacerbations reduced by a third
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of an exacerbation (ie, on average, one in three patients had one
fewer exacerbations). Using a 5% significance level and 90%
power, it is calculated that 97 subjects are required for the study.
It is estimated that two-thirds of available patients will agree to
participate and complete the study. Therefore, to obtain the
calculated number of patients, approximately 150 patients will
be approached to participate. This is approximately the same
number of patients who are likely to attend the MISSION clinics.
Recruitment
Patients
All patients who are booked to come to the MISSION clinic
will receive a MISSION COPD Participant Information Sheet
(PIS) with their booking letter. They will be sent this letter at
least a week prior to the appointment.
At the end of the MISSION COPD clinic, all patients will be
asked if they wish to enroll in the study and will be given the
opportunity to ask questions. If they wish to take part, they will
be consented by a member of the research team who will be at
the MISSION COPD clinic.
Health Care Professionals
Health care professionals who attend the MISSION clinics
(excluding the research team) will be sent a PIS in advance of
the clinic. The initial contact and PIS will be made by a clinical
administrator rather than the PI or CI. If they wish to take part,
they will be consented by a member of the research team at the
MISSION COPD clinic.
Screening and Enrollment
Quantitative Data
All patients who attend the clinic will be approached for consent
having received a PIS prior to the clinic. They will be given the
opportunity to discuss the study with a member of the research
team and, if they wish, will be able to take the consent form
away and send it back in a stamped addressed envelope. If a
patient takes the consent form away to fill in at home, they will
be contacted by telephone after 2 weeks as a reminder. If at this
point they do not wish to take part, they will not be contacted
for the study again.
Patients who attend will be asked to fill in follow-up
questionnaires at 3 and 6 months by mail. All participants will
be asked to complete a self-completion questionnaire on their
experience and views of the MISSION clinic (eg, how they feel
managing their COPD, do they get enough support from
GP/hospital/practice nurse, how they rate the MISSION clinic
with free text for comments).
Qualitative Data
Patients
All patients will be approached for consent having received a
PIS prior to the clinic. They will be given the opportunity to
discuss the study with a member of the research team and, if
they wish, will be able to take the consent form away and send
it back in a stamped addressed envelope. If a patient takes the
consent form away to fill in at home, they will be contacted
after 2 weeks by telephone as a reminder. If at this point they
do not wish to take part, they will not be contacted for the study
again.
All participants in the study will be invited to take part but may
not be selected for interview as we will select on the basis of
multiple variation using a grid to map (for example)
representation of male/females, age range, job status, and new
or existing diagnosis of COPD. We anticipate that there will be
up to 30 interviews.
Health Care Professionals
All health care professionals will be approached for consent
having received a PIS prior to the clinic by email or post. The
PIS will be sent by a clinical administrator rather than the
Principal Investigator or Chief Investigator. They will be given
the opportunity to discuss the study with a member of the
research team.
All health care professionals will be asked if they wish to take
part in a focus group meeting at the end of the clinic to discuss
positives and negatives of the clinic, any improvements, and
any suggestion for development in the future. All health care
professionals who wish to take part will be included. There will
be approximately 11-20 health care professionals at each clinic
from both primary and secondary care. An approximate target
of 20 health care professionals has been set (three per clinic)
with no maximum or minimum number set.
Ethics
The study will not be initiated before the protocol and all study
relevant material such as informed consent forms and participant
and GP information sheets have received approval from the
Research Ethics Committee (REC), and the respective NHS
Research & Development (R&D) department. Any changes to
protocol or relevant study documents will be approved by the
Sponsor. Should an amendment be made that requires REC
approval, as defined by REC as a substantial amendment, the
changes will not be instituted until the amendment has been
reviewed and received approval from the REC and R&D
departments. A protocol amendment intended to eliminate an
apparent immediate hazard to participants may be implemented
immediately providing that the REC are notified as soon as
possible and an approval is requested. Minor amendments, as
defined by REC as nonsubstantial amendment, may be
implemented immediately, and the REC will be informed.
The study staff will ensure that participant anonymity is
maintained. The participants will be identified only by initials
and a participant ID number on the Clinical Record Form and
any electronic database. All documents will be stored securely
and only accessible by study staff and authorized personnel.
The study will comply with the Data Protection Act, which
requires data to be anonymized as soon as it is practical to do
so.
The study will be performed in accordance with the spirit and
letter of the Declaration of Helsinki, the Good Clinical Practice
Guidelines, the protocol, and applicable local regulatory
requirements and laws.
All study staff must hold evidence of appropriate Good Clinical
Practice training or undergo Good Clinical Practice training
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prior to undertaking any responsibilities on this trial. This
training should be updated every 2 years in accordance with
trust policy.
Discontinuation/Withdrawal of Participants
Participants may withdraw at any point in the study during the
6-month follow-up period.
Definition of End of Study
The end of study is the date of the last data collection from GP
record or participant questionnaire 6 months after recruitment.
Interventions
The participants will have attended a new service, the MISSION
clinics, but the care they receive will be no different to standard
care according to local and national guidelines.
The difference of the MISSION clinic is (1) the active case
finding of patients who are not already known to secondary care
but are potentially uncontrolled or who are not known to have
COPD and (2) the model of the clinic. Patients seen at the Rapid
COPD Assessment Clinic only will undergo more extensive
testing and review of their COPD than primary care can provide
and will have their comorbidities identified and treatment
changes made appropriately.
Patients attending the Severe COPD Assessment Clinic are seen
and undergo multidisciplinary review and investigation. The
review includes full lung function, inhaler technique, and
medical review for all patients and physiotherapy, dietitian,
oxygen assessment, CT chest or sinus, psychologist, and
smoking cessation as required. Participants will continue to
receive their standard treatment.
Quantitative Data Collection
Patients
Notes review will be performed after the MISSION clinics to
collect the following data. Where information is not written in
medical notes or clinic letters, it will be marked as not assessed.
Information will include:
• medical history including COPD history, triggers, allergy
history, past medical history, family history, occupation
• lung function
• medication history including COPD and non-COPD
medication for comorbidities and related conditions
• exacerbation history including number of steroid courses,
hospital admissions, and intensive treatment unit admissions
• health care usage including nonroutine GP attendances,
out-of-hour contacts, and ED attendances in 6 months before
and after MISSION SAAC or outpatient clinic
• smoking status and if current smoker, whether any smoking
cessation advice or referral given
• inhaler technique (if on inhaler) – whether checked, any
improvements made, and recommendations for inhaler
devices
• comorbidities assessed
• exercise tolerance (using VSAQ plus clinical history)
• questionnaires (PAM, SGRQ, CAT) at baseline and 3
months for all patients
• questionnaires (VSAQ, PAM, CAT, SGRQ, HADS) at
baseline and 6 months for patients attending Severe COPD
Assessment Clinic
• questionnaires (PAM, CAT, SGRQ) at baseline and 6
months for patients attending Rapid Access COPD Clinics
All participants will be given a self-completion questionnaire,
which will be developed in conjunction with Patient Public
Involvement advisors.
The areas covered will include the participants’ views about
their COPD as well as their views on MISSION using a
combination of questions with Likert-scale responses and free
text answers. The results will be analyzed for content themes
and descriptive statistics such as percentages. The questions
may include, for example:
• How confident do you feel managing your COPD?
• How was the education and care from GP/hospital/practice
nurse?
• How satisfied were you with the booking process for the
clinic / the information that you were given/the team that
welcomed you?
• Would you recommend the clinic to family and friends?
• What would you like to change about the clinic?
• Has the clinic improved your knowledge of COPD?
Health Care Professionals
All health care professional participants will be given a
questionnaire, which will be developed in conjunction with a
Patient Public Involvement advisor. The areas covered will
include their views on MISSION, problems, barriers, and
positive experiences, as well as their experience of COPD care,
education, and areas of good practice and areas for improvement
using Likert scales and free text answers.
Qualitative Assessment
Patients
All patients will be asked if they wish to have a short one-to-one
interview (approximately 30 minutes) to give their views on the
clinic. The interview will be held by a member of the research
team, and the participant will be invited to say anything they
would like to about the clinic. Interviews will be held by
telephone within 2 months of the clinic visit.
Health Care Professionals
All health care professionals will be asked if they wish to attend
a group interview at the end of the clinic to give their views on
the clinic. The interview will be facilitated by a member of the
research team, and the health care professionals will be invited
to say anything they would like to about the clinic they have
just taken part in.
Qualitative Data Analysis
The interviews will be digitally audio recorded and transcribed
by a professional transcription company. The data will be
entered into a software program to facilitate qualitative analysis
(NVivo10). All participants’ names will be removed from the
transcripts to retain confidentiality. When writing the results,
quotes will be used that represent key themes in the data.
However, no quotes will be directly attributed to participants.
JMIR Res Protoc 2017 | vol. 6 | iss. 6 | e104 | p.6http://www.researchprotocols.org/2017/6/e104/
(page number not for citation purposes)
Lanning et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
The data from open-ended questions will be entered into
NVivo10 to facilitate qualitative analysis. All participants’
names will be removed from the data to retain confidentiality.
When writing the results, no quotes will be directly attributed
to participants.
The results from the questionnaires and interview will be
analyzed using a thematic and framework analysis that uses a
5-step approach to analyzing and writing up data [8]. This
involves familiarization with the data, identifying themes,
indexing the themes onto the data, charting, and mapping the
themes. The themes from the patient and health professionals’
questionnaires and interviews can be compared. This will enable
key themes to be systematically identified and to map the themes
from the patients against those from the health care
professionals.
Patient Public Involvement
The MISSION project was developed by members of the clinical
team at Portsmouth after the experience of seeing patients in
clinic. MISSION COPD has been developed after a successful
MISSION asthma project and feedback from patients who
attended.
A patient advisor will review and give feedback on all
patient-facing documentation for the study. A patient volunteer
will be invited to review the PIS and give advice and feedback
on the qualitative questionnaire.
Patient volunteers and patients who have taken part in the study
and express interest will be invited to help with dissemination
events. The results will be submitted for presentation at national
conferences.
All study participants will be given a summary of the study
results in an appropriate format.
Results
The results will be submitted for publication in summer 2017.
Discussion
Principal Considerations
COPD affects over 1 million people in the United Kingdom and
1 person dies from COPD every 20 minutes [1]. The cost to
people with COPD and the NHS is huge—more than 24 million
working days a lost a year and the annual spend on COPD is
£810 million [2].
Portsmouth has a higher rate of smoking, which is the
commonest cause of COPD, as well as a much higher rate of
death caused by smoking than the average for England [4]. Over
900 people were admitted to Portsmouth Hospitals NHS Trust
because of COPD in 2013/2014.
The aim of MISSION COPD is to reduce hospital admissions
and improve peoples’ quality of life. A project in Southampton
where a team looked for people with undiagnosed COPD
reduced hospital admissions even though they increased the
number of people with a diagnosis of COPD [6].
Our clinics will find patients with severe COPD or with
undiagnosed COPD and review them in a one-stop clinic held
at their GP surgery—a Rapid Access COPD Clinic. Patients
who need more tests will then be seen at a Severe COPD
Assessment Clinic at the hospital. Our goal is to see if patients
who come to the MISSION clinics have an improvement in
their COPD symptoms in the 6 months after the clinic compared
to the 6 months before the clinic.
All patients who come to the MISSION COPD clinic will be
asked to participate in the research. There are two parts to the
research – data analysis and interview. All patients will be
invited to take part in both parts, but not everyone will have an
interview. Data will be collected from the notes and entered
onto a record form anonymously, which will then be analyzed.
Interviews will be held over the telephone at a time convenient
to the participant. Health care professionals will be invited to
take part in a focus group interview at the end of the clinic.
Strengths and Limitations
This is a small study that will establish the feasibility and
successes of the MISSION project. As such, it is not powered
for statistical significance. However, its small size allows for
greater review of the process through staff and patient
experiences allowing the model and project to be changed for
future delivery.
Conclusion
This research is important as it will provide evidence to support
the use of the MISSION clinic model for patients with COPD.
It will also give us more information on patients with COPD
and any medical conditions related to their COPD so that we
can adapt our service to meet their needs. The telephone and
group interviews will help us understand what we are doing
right and what we are doing wrong with COPD care.
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CAT: COPD Assessment Test
COPD: chronic obstructive pulmonary disease
CT: computerized tomography
ED: emergency department
ESS: Epworth Sleepiness Score
FEV1: forced expiratory volume in 1s
FVC: forced vital capacity
GERD-Q : Gastroesophageal Reflux Disease Questionnaire
GP: general practitioner or general practice
HADS: Hospital Anxiety and Depression Score
MISSION: Modern Innovative SolutionS Improving Outcomes iN
NHS: National Health Service
NHS-IQ: NHS-Improving Quality
PAM: Patient Activation Measure
PIS: Participant Information Sheet
R&D: Research and Development
REC: Research Ethics Committee
SGRQ: St George’s Respiratory Questionnaire
VSAQ: Veterans Specific Activity Questionnaire
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